![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Author: Khasnavis Saurabh Roy Avik Ghosh Supurna Watson Richard Pahan Kalipada
Publisher: Springer Publishing Company
ISSN: 1557-1890
Source: Journal of Neuroimmune Pharmacology, Vol.9, Iss.2, 2014-03, pp. : 218-232
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Related content
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Dopaminergic substitution in Parkinson’s disease
Expert Opinion on Pharmacotherapy, Vol. 3, Iss. 10, 2002-10 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
CNS & Neurological Disorders - Drug Targets (Formerly Current Drug Targets - CNS & Neurological Disorders), Vol. 6, Iss. 4, 2007-08 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Non-dopaminergic drug treatment of Parkinson’s disease
By Müller T.
Expert Opinion on Pharmacotherapy, Vol. 2, Iss. 4, 2001-04 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Existing dopaminergic therapies for Parkinson’s disease
By Dutta PhD Aloke K Le MD PhD Weidong
Expert Opinion on Therapeutic Patents, Vol. 16, Iss. 12, 2006-12 ,pp. :